NanoViricides Inc. (NNVC)

[changes_iv]

The important bits and pieces of NanoViricides, Inc. PRs...

NanoViricides, Inc. Reports Excellent Safety Profile of Its Broad-Spectrum anti-Influenza Drug Candidate, FluCide(TM) , in a Non-GLP Study

As previously reported, the results of this study will provide both the basis and focus for the GLP safety and toxicology studies of FluCide that are required for the IND submission to the U.S. FDA. These GLP studies will be performed on both large and small animals at the BASi facility in Indiana.

We are currently focusing on advancing our Injectable FluCide™ drug, for the treatment of severely ill, hospitalized, influenza patients, towards an IND filing. We have also developed an Oral FluCide drug that continues to advance following the injectable version. Both of our FluCide drug candidates are “broad-spectrum”, i.e. they are expected to be able to combat most, if not all, influenza viruses, including bird flu, high path influenzas, epidemic influenzas, seasonal influenzas, and potentially any novel influenza A strains.

The Company is scaling up the production of FluCide from gram scale to several hundred grams scale. The Company believes that the scale up and reproducibility of product batches can be effectively controlled.

If toxic Marijuana is getting licensed in states without a challenge from the Department of Justice, low-toxicity and life-saving NanoViricides, Inc. FluCide should find its way to market and soon. NanoViricides, Inc. is in a race to market. They are frugal and spend their money judiciously. Remarkable news are forthcoming.

How long do drugs stay in your system? How long will FluCide? A week, two weeks?